
Sang-Cheol Bae

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9411333/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	3.4	7
2	Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study. Arthritis Care and Research, 2022, 74, 2033-2041.	3.4	6
3	Human SLE variant <i>NCF1</i> -R90H promotes kidney damage and murine lupus through enhanced Tfh2 responses induced by defective efferocytosis of macrophages. Annals of the Rheumatic Diseases, 2022, 81, 255-267.	0.9	14
4	Novel susceptibility loci for steroid-associated osteonecrosis of the femoral head in systemic lupus erythematosus. Human Molecular Genetics, 2022, 31, 1082-1095.	2.9	1
5	Recent advances in understanding the genetic basis of systemic lupus erythematosus. Seminars in Immunopathology, 2022, 44, 29-46.	6.1	27
6	Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). Modern Rheumatology, 2022, 32, 263-272.	1.8	10
7	Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study. RMD Open, 2022, 8, e001892.	3.8	8
8	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.9	42
9	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.9	9
10	â€~Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. Arthritis Research and Therapy, 2022, 24, 70.	3.5	17
11	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatology, The, 2022, 4, e441-e449.	3.9	17
12	Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study. Annals of the Rheumatic Diseases, 2022, 81, 1273-1280.	0.9	9
13	Predictive Factors for Renal Response in Lupus Nephritis: A Single-center Prospective Cohort Study. Journal of Rheumatic Diseases, 2022, 29, 223-231.	1.1	3
14	Safety and tolerability of bone marrow–derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans. Lupus, 2022, 31, 1245-1253.	1.6	3
15	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	3.4	13
16	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	3.4	22
17	Association of HLA-G polymorphisms with systemic lupus erythematosus and correlation between soluble HLA‑G levels and the disease: aÂmeta-analysis. Zeitschrift Fur Rheumatologie, 2021, 80, 96-102.	1.0	9
18	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. Annals of the Rheumatic Diseases, 2021, 80, 1.1-2.	0.9	31

#	Article	IF	CITATIONS
19	Alleleâ€6pecific Quantification of HLA–DRB1 Transcripts Reveals Imbalanced Allelic Expression That Modifies the Amino Acid Effects in HLA–DRβ1. Arthritis and Rheumatology, 2021, 73, 381-391.	5.6	4
20	Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2021, 80, 632-640.	0.9	103
21	Large-scale meta-analysis across East Asian and European populations updated genetic architecture and variant-driven biology of rheumatoid arthritis, identifying 11 novel susceptibility loci. Annals of the Rheumatic Diseases, 2021, 80, 558-565.	0.9	93
22	Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study. Journal of Korean Medical Science, 2021, 36, e70.	2.5	7
23	Fracture Risk and its Prevention Patterns in Korean Patients with Polymyalgia Rheumatica: a Retrospective Cohort Study. Journal of Korean Medical Science, 2021, 36, e263.	2.5	2
24	Genetic variants shape rheumatoid arthritis-specific transcriptomic features in CD4 ⁺ T cells through differential DNA methylation, explaining a substantial proportion of heritability. Annals of the Rheumatic Diseases, 2021, 80, 876-883.	0.9	12
25	Characteristics in Pediatric Patients with Coronavirus Disease 2019 in Korea. Journal of Korean Medical Science, 2021, 36, e148.	2.5	6
26	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. Lupus Science and Medicine, 2021, 8, e000433.	2.7	7
27	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology, 2021, 60, 4737-4747.	1.9	14
28	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	1.6	3
29	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	5.6	7
30	Lupus Susceptibility Region Containing <i>CDKN1B</i> rs34330 Mechanistically Influences Expression and Function of Multiple Target Genes, Also Linked to Proliferation and Apoptosis. Arthritis and Rheumatology, 2021, 73, 2303-2313.	5.6	11
31	Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open, 2021, 7, e001629.	3.8	17
32	Mortality in Korean Patients With Rheumatoid Arthritis. Journal of Rheumatic Diseases, 2021, 28, 113-118.	1.1	13
33	Clinical and Genetic Risk Factors Associated With the Presence of Lupus Nephritis. Journal of Rheumatic Diseases, 2021, 28, 150-158.	1.1	7
34	Excess mortality persists in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2021, 24, 364-372.	1.9	23
35	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Annals of the Rheumatic Diseases, 2021, 80, 848-858.	0.9	123
36	Risk Factors of Outcomes of COVID-19 Patients in Korea: Focus on Early Symptoms. Journal of Korean Medical Science, 2021, 36, e132.	2.5	13

#	Article	IF	CITATIONS
37	1124â€Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
38	1107â€Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
39	801â€Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk. , 2021, , .		0
40	1704â€Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
41	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	2.7	97
42	Intractable Progressive Cerebral Infarction with Multiple Atypical Aneurysms in Systemic Lupus Erythematosus. Journal of Neurosonology and Neuroimaging, 2021, 13, 71-75.	0.1	0
43	Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis. Korean Journal of Internal Medicine, 2021, , .	1.7	0
44	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	2.7	31
45	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	2.0	34
46	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	5.6	39
47	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	3.4	23
48	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	5.6	26
49	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	6.5	27
50	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.9	40
51	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine, 2020, 382, 211-221.	27.0	725
52	Identifying damage clusters in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2020, 23, 84-91.	1.9	6
53	An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. Seminars in Arthritis and Rheumatism, 2020, 50, 526-533.	3.4	24
54	P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results. Rheumatology, 2020, 59, .	1.9	1

#	Article	IF	CITATIONS
55	Genome-wide association study in a Korean population identifies six novel susceptibility loci for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 1438-1445.	0.9	26
56	COVIDâ€19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. International Journal of Rheumatic Diseases, 2020, 23, 1255-1257.	1.9	12
57	Phorbol ester activates human mesenchymal stem cells to inhibit B cells and ameliorate lupus symptoms in MRL. <i>Fas</i> ^{lpr} mice. Theranostics, 2020, 10, 10186-10199.	10.0	10
58	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	3.4	9
59	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	5.6	17
60	Effect of Human Mesenchymal Stem Cells on Xenogeneic T and B Cells Isolated from Lupus-Prone MRL.Faslpr Mice. Stem Cells International, 2020, 2020, 1-10.	2.5	11
61	Synergistic activation of NF-l [®] B by TNFAIP3 (A20) reduction and UBE2L3 (UBCH7) augment that synergistically elevate lupus risk. Arthritis Research and Therapy, 2020, 22, 93.	3.5	15
62	Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies. Journal of Korean Medical Science, 2020, 35, e335.	2.5	4
63	Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	3.4	70
64	Associations between paraoxonase-1 and systemic lupus erythematosus. Lupus, 2019, 28, 1571-1576.	1.6	2
65	Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 195.	3.5	1
66	Association between CD40 polymorphisms and systemic lupus erythematosus and correlation between soluble CD40 and CD40 ligand levels in the disease: a meta-analysis. Lupus, 2019, 28, 1452-1459.	1.6	6
67	Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values. International Journal of Rheumatic Diseases, 2019, 22, 852-859.	1.9	0
68	Causal association between body mass index and risk of rheumatoid arthritis: A Mendelian randomization study. European Journal of Clinical Investigation, 2019, 49, e13076.	3.4	32
69	Causal relationship between years of education and the occurrence of rheumatoid arthritis. Postgraduate Medical Journal, 2019, 95, 378-381.	1.8	10
70	Increased risk of opportunistic infection in early rheumatoid arthritis. International Journal of Rheumatic Diseases, 2019, 22, 1239-1246.	1.9	11
71	Prevalence and predictors for sustained remission in rheumatoid arthritis. PLoS ONE, 2019, 14, e0214981.	2.5	12
72	Amino acid signatures of HLA Class-I and II molecules are strongly associated with SLE susceptibility and autoantibody production in Eastern Asians. PLoS Genetics, 2019, 15, e1008092.	3.5	36

#	Article	IF	CITATIONS
73	Associations between paraoxonase 1 (PON1) polymorphisms and susceptibility and PON1 activity in rheumatoid arthritis patients, and comparison of PON1 activity in patients and controls: a meta-analysis. Clinical Rheumatology, 2019, 38, 2141-2149.	2.2	9
74	Development of a Paper-Based Viscometer for Blood Plasma Using Colorimetric Analysis. Analytical Chemistry, 2019, 91, 4868-4875.	6.5	16
75	Understanding HLA associations from SNP summary association statistics. Scientific Reports, 2019, 9, 1337.	3.3	9
76	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	5.6	25
77	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	1.9	8
78	267â€Relative expression strength of HLA-DRB1 in heterozygotes is associated with rheumatic diseases. , 2019, , .		0
79	AB1273â€ESTABLISHMENT OF A PROSPECTIVE COHORT FOR RHEUMATOID ARTHRITIS PATIENTS WITH INTERSTITIAL LUNG DISEASE: COMPARISON OF BASELINE CHARACTERISTICS BETWEEN RHEUMATOID ARTHRITIS PATIENT WITH OR WITHOUT INTERSTITIAL LUNG DISEASE. , 2019, , .		О
80	LB0001â€EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQ RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS. , 2019, , .	UATE	15
81	52â€Contact dynamics between mesenchymal stem cells and T cells in lupus-prone MRL/lpr mouse model. , 2019, , .		О
82	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. Lupus Science and Medicine, 2019, 6, e000342.	2.7	15
83	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.9	12
84	Development of the Asia Pacific Lupus Collaboration cohort. International Journal of Rheumatic Diseases, 2019, 22, 425-433.	1.9	24
85	Relationship between cerebral microbleeds and white matter MR hyperintensities in systemic lupus erythematosus: a retrospective observational study. Neuroradiology, 2019, 61, 265-274.	2.2	2
86	High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis. Patient, 2019, 12, 319-326.	2.7	1
87	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	5.6	55
88	Factors associated with time to diagnosis from symptom onset in patients with early rheumatoid arthritis. Korean Journal of Internal Medicine, 2019, 34, 910-916.	1.7	19
89	Mesenchymal Stem Cells Ameliorate Renal Inflammation in Adriamycin-induced Nephropathy. Immune Network, 2019, 19, e36.	3.6	14
90	Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study. Clinical and Experimental Rheumatology, 2019, 37, 89-96.	0.8	9

#	Article	IF	CITATIONS
91	Vitamin D receptor Fokl, Taql, and Apal polymorphisms and susceptibility to systemic lupus erythematosus: an updated meta-analysis. Clinical Rheumatology, 2018, 37, 1529-1537.	2.2	13
92	Comparative efficacy and safety of biosimilarâ€infliximab and originatorâ€infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a metaâ€analysis of randomized controlled trials. International Journal of Rheumatic Diseases, 2018, 21, 922-929.	1.9	7
93	A plausibly causal functional lupus-associated risk variant in the STAT1–STAT4 locus. Human Molecular Genetics, 2018, 27, 2392-2404.	2.9	34
94	Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil. International Journal of Rheumatic Diseases, 2018, 21, 1031-1039.	1.9	14
95	Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Clinical Rheumatology, 2018, 37, 1199-1205.	2.2	10
96	Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Clinical Rheumatology, 2018, 37, 1471-1479.	2.2	18
97	TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis. Zeitschrift Fur Rheumatologie, 2018, 77, 824-832.	1.0	7
98	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 393-396.	2.0	27
99	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	1.9	37
100	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	3.4	55
101	Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization. Rheumatology International, 2018, 38, 649-656.	3.0	48
102	A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Annals of the Rheumatic Diseases, 2018, 77, 355-363.	0.9	196
103	Glucocorticoids Are Associated with an Increased Risk for Vertebral Fracture in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2018, 45, 612-620.	2.0	20
104	Correlation between circulating VEGF levels and disease activity in rheumatoid arthritis: aÂmeta-analysis. Zeitschrift Fur Rheumatologie, 2018, 77, 240-248.	1.0	36
105	Nonâ€aneurysmal subarachnoid hemorrhage in two patients with systemic lupus erythematosus: Case reports and literature review. International Journal of Rheumatic Diseases, 2018, 21, 761-766.	1.9	5
106	Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with diseaseâ€modifying antiâ€rheumatic drugs for at least 6 months. International Journal of Rheumatic Diseases, 2018, 21, 1001-1009.	1.9	5
107	Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: A metaâ€analysis. International Journal of Rheumatic Diseases, 2018, 21, 664-672.	1.9	60
108	Clinical characteristics of multifocal osteonecrosis in Korean patients with rheumatic disease. International Journal of Rheumatic Diseases, 2018, 21, 1301-1308.	1.9	8

#	Article	IF	CITATIONS
109	Association of CD8 ⁺ T ells with bone erosion in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2018, 21, 440-446.	1.9	7
110	Comparative efficacy and tolerability of monotherapy with leflunomide or tacrolimus for the treatment of rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Clinical Rheumatology, 2018, 37, 323-330.	2.2	4
111	Associations between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis, and between <i>MIF</i> gene polymorphisms and disease susceptibility: a meta-analysis. Postgraduate Medical Journal, 2018, 94, 109-115.	1.8	28
112	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	3.4	21
113	Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2018, 47, 501-506.	3.4	13
114	Productivity Loss of Rheumatoid Arthritis Patients according to the Their Stages of the Disease Activity Score. Journal of Rheumatic Diseases, 2018, 25, 122.	1.1	2
115	Strategies for the safe use of non-steroidal anti-inflammatory drugs. Journal of the Korean Medical Association, 2018, 61, 367.	0.3	6
116	CS-07â€Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
117	Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea. Journal of Korean Medical Science, 2018, 33, e346.	2.5	5
118	Coffee consumption and the risk of rheumatoid arthritis and systemic lupus erythematosus: a Mendelian randomization study. Clinical Rheumatology, 2018, 37, 2875-2879.	2.2	17
119	Vitamin D level and risk of systemic lupus erythematosus and rheumatoid arthritis: a Mendelian randomization. Clinical Rheumatology, 2018, 37, 2415-2421.	2.2	37
120	Effect of a Combination of Prednisone or Mycophenolate Mofetil and Mesenchymal Stem Cells on Lupus Symptoms in MRL. <i>Fas</i> ^{lpr} Mice. Stem Cells International, 2018, 2018, 1-10.	2.5	12
121	MiRâ€146a levels in rheumatoid arthritis and their correlation with disease activity: a metaâ€analysis. International Journal of Rheumatic Diseases, 2018, 21, 1335-1342.	1.9	42
122	Genetic variants in systemic lupus erythematosus susceptibility loci, XKR6 and GLT1D1 are associated with childhood-onset SLE in a Korean cohort. Scientific Reports, 2018, 8, 9962.	3.3	25
123	IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis. Arthritis Research and Therapy, 2018, 20, 115.	3.5	116
124	Comparison of screening strategies for prevalent vertebral fractures in South Korea: vertebral fracture assessment vs. spine radiography. BMC Musculoskeletal Disorders, 2018, 19, 46.	1.9	4
125	Association between Vitamin D level and/or deficiency, and systemic lupus erythematosus: a meta-analysis. Cellular and Molecular Biology, 2018, 64, 7-13.	0.9	23
126	Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy. Korean Journal of Internal Medicine, 2018, 33, 1016-1024.	1.7	3

#	Article	lF	CITATIONS
127	Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis. Cellular and Molecular Biology, 2018, 64, 46-51.	0.9	5
128	Meta-analysis of gene expression profiles of peripheral blood cells in systemic lupus erythematosus. Cellular and Molecular Biology, 2018, 64, 40-49.	0.9	8
129	A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Annals of the Rheumatic Diseases, 2017, 76, 65-71.	0.9	39
130	What factors affect discordance between physicians and patients in the global assessment of disease activity in rheumatoid arthritis?. Modern Rheumatology, 2017, 27, 35-41.	1.8	16
131	Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment. Seminars in Arthritis and Rheumatism, 2017, 47, 102-107.	3.4	11
132	Associations between circulating IL-17 levels and rheumatoid arthritis and between IL-17 gene polymorphisms and disease susceptibility: a meta-analysis. Postgraduate Medical Journal, 2017, 93, 465-471.	1.8	32
133	A missense variant in NCF1 is associated with susceptibility to multiple autoimmune diseases. Nature Genetics, 2017, 49, 433-437.	21.4	143
134	Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab. Rheumatology International, 2017, 37, 1007-1014.	3.0	10
135	Predictors of severe radiographic progression in patients with early rheumatoid arthritis: A Prospective observational cohort study. International Journal of Rheumatic Diseases, 2017, 20, 1437-1446.	1.9	10
136	Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis. Postgraduate Medicine, 2017, 129, 531-537.	2.0	30
137	Confirmation of five novel susceptibility loci for Systemic Lupus Erythematosus (SLE) and integrated network analysis of 82 SLE susceptibility loci. Human Molecular Genetics, 2017, 26, ddx026.	2.9	47
138	CCL2 deficient mesenchymal stem cells fail to establish long-lasting contact with T cells and no longer ameliorate lupus symptoms. Scientific Reports, 2017, 7, 41258.	3.3	35
139	Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis. Rheumatology International, 2017, 37, 1735-1745.	3.0	43
140	Update on the genetic architecture of rheumatoid arthritis. Nature Reviews Rheumatology, 2017, 13, 13-24.	8.0	102
141	Association between Functional CYP2D6 Polymorphisms and Susceptibility to Autoimmune Diseases: A Meta-Analysis. Immunological Investigations, 2017, 46, 109-122.	2.0	14
142	Clinical characteristics and outcomes of diffuse alveolar hemorrhage in patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2017, 46, 782-787.	3.4	36
143	The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs. Arthritis Research and Therapy, 2017, 19, 277.	3.5	19
144	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	3.5	1

#	Article	IF	CITATIONS
145	<i>ABCG2</i> Polymorphism Is Associated with Hyperuricemia in a Study of a Community-Based Korean Cohort. Journal of Korean Medical Science, 2017, 32, 1451.	2.5	9
146	Biological function integrated prediction of severe radiographic progression in rheumatoid arthritis: a nested case control study. Arthritis Research and Therapy, 2017, 19, 244.	3.5	11
147	Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation for Refractory Rheumatic Diseases. Journal of Rheumatic Diseases, 2017, 24, 149.	1.1	1
148	Impact of early diagnosis on functional disability in rheumatoid arthritis. Korean Journal of Internal Medicine, 2017, 32, 738-746.	1.7	15
149	Pharmacologic treatment of rheumatoid arthritis. Journal of the Korean Medical Association, 2017, 60, 156.	0.3	4
150	Ulnar artery vasculopathy: a common but nonspecific feature of systemic sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 221-224.	1.7	0
151	Brief Report: Influence of HLA–DRB1 Susceptibility Alleles on the Clinical Subphenotypes of Systemic Lupus Erythematosus in Koreans. Arthritis and Rheumatology, 2016, 68, 1190-1196.	5.6	17
152	Identification of a Systemic Lupus Erythematosus Risk Locus Spanning <i>ATG16L2, FCHSD2</i> , and <i>P2RY2</i> in Koreans. Arthritis and Rheumatology, 2016, 68, 1197-1209.	5.6	89
153	Agreement of Major Diagnosis and Comorbidity between Self-reported Questionnaire and Medical Record Review in Patients with Rheumatic Disease. Journal of Rheumatic Diseases, 2016, 23, 348.	1.1	1
154	Factors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid Arthritis. Journal of Korean Medical Science, 2016, 31, 1907.	2.5	7
155	Prevalence and possible causes of hypouricemia at a tertiary care hospital. Korean Journal of Internal Medicine, 2016, 31, 971-976.	1.7	23
156	Association of Complement Receptor 2 Gene Polymorphisms with Susceptibility to Osteonecrosis of the Femoral Head in Systemic Lupus Erythematosus. BioMed Research International, 2016, 2016, 1-6.	1.9	9
157	Impact of Childbearing Decisions on Family Size of Korean Women with Systemic Lupus Erythematosus. Journal of Korean Medical Science, 2016, 31, 729.	2.5	5
158	Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network metaâ€analysis of randomized controlled trials. International Journal of Rheumatic Diseases, 2016, 19, 1103-1111.	1.9	41
159	Genomeâ€Wide Association Study in an Amerindian Ancestry Population Reveals Novel Systemic Lupus Erythematosus Risk Loci and the Role of European Admixture. Arthritis and Rheumatology, 2016, 68, 932-943.	5.6	138
160	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis and Rheumatology, 2016, 68, 1932-1944.	5.6	40
161	Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data. Rheumatology International, 2016, 36, 505-513.	3.0	18
162	Incidence and risk factors of fractures in patients with rheumatoid arthritis: an Asian prospective cohort study. Rheumatology International, 2016, 36, 1205-1214.	3.0	35

#	Article	IF	CITATIONS
163	The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis. BMC Musculoskeletal Disorders, 2016, 17, 98.	1.9	38
164	Contribution of a Non-classical HLA Gene, HLA-DOA, to the Risk of Rheumatoid Arthritis. American Journal of Human Genetics, 2016, 99, 366-374.	6.2	68
165	Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Rheumatology International, 2016, 36, 1591-1599.	3.0	35
166	Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis. BMC Musculoskeletal Disorders, 2016, 17, 333.	1.9	28
167	Association-heterogeneity mapping identifies an Asian-specific association of the GTF2I locus with rheumatoid arthritis. Scientific Reports, 2016, 6, 27563.	3.3	23
168	Differences in Clinical Features and Mortality between Childhood-onset and Adult-onset Systemic Lupus Erythematosus: A Prospective Single-center Study. Journal of Rheumatology, 2016, 43, 1490-1497.	2.0	39
169	Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity. Arthritis Research and Therapy, 2016, 18, 1.	3.5	80
170	High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry. Nature Genetics, 2016, 48, 323-330.	21.4	219
171	Decreased <i>SMG7</i> expression associates with lupus-risk variants and elevated antinuclear antibody production. Annals of the Rheumatic Diseases, 2016, 75, 2007-2013.	0.9	16
172	Response to Intravenous Cyclophosphamide Treatment for Lupus Nephritis Associated with Polymorphisms in the <i>FCGR2B-FCRLA</i> Locus. Journal of Rheumatology, 2016, 43, 1045-1049.	2.0	15
173	Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity—results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology, 2016, 26, 651-661.	1.8	24
174	Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. Annals of the Rheumatic Diseases, 2016, 75, 242-252.	0.9	10
175	The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, 2016, 55, 252-262.	1.9	370
176	Association between the functional MHC2TA â^'168 A/G polymorphism and susceptibility to rheumatoid arthritis: a meta-analysis. Clinical Rheumatology, 2016, 35, 901-909.	2.2	2
177	Imputing Variants in HLA-DR Beta Genes Reveals That HLA-DRB1 Is Solely Associated with Rheumatoid Arthritis and Systemic Lupus Erythematosus. PLoS ONE, 2016, 11, e0150283.	2.5	20
178	Diagnostic accuracy of lung ultrasound for interstitial lung disease in patients with connective tissue diseases: a meta-analysis. Clinical and Experimental Rheumatology, 2016, 34, 11-6.	0.8	31
179	Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: a meta-analysis. Clinical and Experimental Rheumatology, 2016, 34, 827-833.	0.8	66
180	An HLA-C amino-acid variant in addition to HLA-B*27 confers risk for ankylosing spondylitis in the Korean population. Arthritis Research and Therapy, 2015, 17, 342.	3.5	21

#	Article	IF	CITATIONS
181	Interactions Between Amino Acid–Defined Major Histocompatibility Complex Class II Variants and Smoking in Seropositive Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2611-2623.	5.6	58
182	Incidence of Tuberculosis in Rheumatoid Arthritis Patients Using Anti-Tumor Necrosis Factor Agents following Latent Tuberculosis Infection Screening Strategies. Journal of Rheumatic Diseases, 2015, 22, 223.	1.1	3
183	DC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice. Journal of Immunology Research, 2015, 2015, 1-15.	2.2	12
184	High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. Annals of the Rheumatic Diseases, 2015, 74, e13-e13.	0.9	100
185	Lupus risk variants in the PXK locus alter B-cell receptor internalization. Frontiers in Genetics, 2015, 5, 450.	2.3	25
186	Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression. American Journal of Human Genetics, 2015, 96, 731-739.	6.2	36
187	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	5.6	98
188	Direct medical costs and their predictors in South Korean patients with systemic lupus erythematosus. Rheumatology International, 2015, 35, 1809-1815.	3.0	17
189	Clinical validation of surface-enhanced Raman scattering-based immunoassays in the early diagnosis of rheumatoid arthritis. Analytical and Bioanalytical Chemistry, 2015, 407, 8353-8362.	3.7	18
190	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. Clinical Immunology, 2015, 161, 157-162.	3.2	10
191	Factors Associated with the Use of Complementary and Alternative Medicine for Korean Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 2075-2081.	2.0	19
192	Association between FCGR3B copy number variations and susceptibility to autoimmune diseases: a meta-analysis. Inflammation Research, 2015, 64, 983-991.	4.0	14
193	The IRF5–TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Human Molecular Genetics, 2015, 24, 582-596.	2.9	74
194	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.9	70
195	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.9	391
196	Construction and Application of a Korean Reference Panel for Imputing Classical Alleles and Amino Acids of Human Leukocyte Antigen Genes. PLoS ONE, 2014, 9, e112546.	2.5	27
197	The Influence of Vertebral Fracture on the Functional Disability of Patients with Rheumatoid Arthritis. Journal of Korean Medical Science, 2014, 29, 859.	2.5	5
198	The Role of Bone Scintigraphy in the Diagnosis of Rheumatoid Arthritis According to the 2010 ACR/EULAR Classification Criteria. Journal of Korean Medical Science, 2014, 29, 204.	2.5	16

#	Article	IF	CITATIONS
199	The HLA-DRβ1 amino acid positions 11–13–26 explain the majority of SLE–MHC associations. Nature Communications, 2014, 5, 5902.	12.8	80
200	Development of rheumatoid arthritis specific HLA-DRB1 genotyping microarray. Biochip Journal, 2014, 8, 187-198.	4.9	1
201	Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations. Human Molecular Genetics, 2014, 23, 1656-1668.	2.9	67
202	Two Functional Lupus-Associated BLK Promoter Variants Control Cell-Type- and Developmental-Stage-Specific Transcription. American Journal of Human Genetics, 2014, 94, 586-598.	6.2	59
203	The frequency of single nucleotide polymorphisms and their association with uric acid concentration based on data from genome-wide association studies in the Korean population. Rheumatology International, 2014, 34, 777-783.	3.0	6
204	Prevalence and incidence of systemic lupus erythematosus in South Korea. Rheumatology International, 2014, 34, 909-917.	3.0	37
205	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Annals of the Rheumatic Diseases, 2014, 73, 138-142.	0.9	115
206	Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature, 2014, 506, 376-381.	27.8	1,974
207	SERS-based immunoassay of anti-cyclic citrullinated peptide for early diagnosis of rheumatoid arthritis. RSC Advances, 2014, 4, 32924-32927.	3.6	17
208	Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Human Molecular Genetics, 2014, 23, 6916-6926.	2.9	135
209	Improving Participation in Clinical Trials of Novel Therapies. Rheumatic Disease Clinics of North America, 2014, 40, 553-559.	1.9	4
210	Validity and role of vertebral fracture assessment in detecting prevalent vertebral fracture in patients with rheumatoid arthritis. Joint Bone Spine, 2014, 81, 149-153.	1.6	11
211	Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?. Korean Journal of Internal Medicine, 2014, 29, 509.	1.7	5
212	Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials. Korean Journal of Internal Medicine, 2014, 29, 656.	1.7	27
213	Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskeletal Disorders, 2013, 14, 13.	1.9	38
214	Prevalence and incidence of rheumatoid arthritis in South Korea. Rheumatology International, 2013, 33, 1525-1532.	3.0	62
215	Cancer risk in systemic lupus: An updated international multi-centre cohort study. Journal of Autoimmunity, 2013, 42, 130-135.	6.5	249
216	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. Arthritis and Rheumatism, 2013, 65, 2887-2897.	6.7	84

#	Article	IF	CITATIONS
217	Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database. Rheumatology International, 2013, 33, 2985-2992.	3.0	78
218	Factors Influencing Discrepancies Between the QuantiFERON-TB Gold in Tube Test and the Tuberculin Skin Test in Korean Patients with Rheumatic Diseases. Seminars in Arthritis and Rheumatism, 2013, 42, 424-432.	3.4	31
219	Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. International Journal of Rheumatic Diseases, 2013, 16, 527-531.	1.9	90
220	Association of genetic polymorphisms in CD40 with susceptibility to SLE in the Korean population. Rheumatology, 2013, 52, 623-630.	1.9	22
221	Diagnosis and Treatment of Lupus Nephritis: Survey Results on Four Important Issues. Journal of Rheumatic Diseases, 2013, 20, 156.	1.1	1
222	Long-term Safety and Efficacy of Abatacept in Koreans with Rheumatoid Arthritis. Journal of Rheumatic Diseases, 2013, 20, 30.	1.1	1
223	Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus. Autoimmune Diseases, 2012, 2012, 1-6.	0.6	18
224	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.9	143
225	Biologics use in sle in 23 centers – data from the international registry for biologics in SLE. Annals of the Rheumatic Diseases, 2012, 71, A9.1-A9.	0.9	1
226	Mortality and Incidence of Malignancy in Korean Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 226-232.	2.0	32
227	Genome-wide pathway analysis of genome-wide association studies on systemic lupus erythematosus and rheumatoid arthritis. Molecular Biology Reports, 2012, 39, 10627-10635.	2.3	114
228	Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nature Genetics, 2012, 44, 291-296.	21.4	768
229	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
230	Associations between TNFAIP3 gene polymorphisms and rheumatoid arthritis: a meta-analysis. Inflammation Research, 2012, 61, 635-641.	4.0	42
231	Korean Observational Study Network for Arthritis (KORONA): Establishment of a Prospective Multicenter Cohort for Rheumatoid Arthritis in South Korea. Seminars in Arthritis and Rheumatism, 2012, 41, 745-751.	3.4	54
232	Systematic review of the epidemiology of systemic lupus erythematosus in the Asiaâ€Pacific region: Prevalence, incidence, clinical features, and mortality. Arthritis Care and Research, 2012, 64, 159-168.	3.4	260
233	Impact of Change in Reimbursement Guideline of Rheumatoid Arthritis on the Short Term Persistence of Tumor Necrosis Factor (TNF) Blockers. Journal of Rheumatic Diseases, 2011, 18, 283.	1.1	4
234	Treatment Persistence with TNF Blocker in Korean Rheumatoid Arthritis Patients. Journal of Rheumatic Diseases, 2011, 18, 161.	1.1	3

#	Article	IF	CITATIONS
235	Genomeâ€wide association study of rheumatoid arthritis in Koreans: Populationâ€specific loci as well as overlap with European susceptibility loci. Arthritis and Rheumatism, 2011, 63, 884-893.	6.7	121
236	The Current Status of Surveys on Prevalence of Rheumatic Diseases in Korea. The Journal of the Korean Rheumatism Association, 2010, 17, 1.	0.1	11
237	Rheumatoid arthritis: past, present and future. Journal of the Korean Medical Association, 2010, 53, 842.	0.3	1
238	TNF Inhibitors and Uveitis in Ankylosing Spondylitis. The Journal of the Korean Rheumatism Association, 2009, 16, 48.	0.1	1
239	Genetic risk factors for rheumatoid arthritis differ in caucasian and Korean populations. Arthritis and Rheumatism, 2009, 60, 364-371.	6.7	109
240	Effects of Antioxidant Supplements Intervention on the Level of Plasma Inflammatory Molecules and Disease Severity of Rheumatoid Arthritis Patients. Journal of the American College of Nutrition, 2009, 28, 56-62.	1.8	86
241	Characteristics of Korean Patients with RA: A Single Center Cohort Study. The Journal of the Korean Rheumatism Association, 2009, 16, 204.	0.1	10
242	Cost-effectiveness of Early Use of Etanercept in the Treatment of Rheumatoid Arthritis. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2009, 17, 93.	0.1	0
243	The Prevalence and Trend of Arthritis in Korea: Results from Korea National Health and Nutrition Examination Surveys. The Journal of the Korean Rheumatism Association, 2008, 15, 11.	0.1	42
244	Water Intoxication Following Low-Dose Intravenous Cyclophosphamide. Electrolyte and Blood Pressure, 2007, 5, 50.	1.8	8
245	Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. Journal of Rheumatology, 2007, 34, 706-11.	2.0	131
246	Clinical experience with tumor necrosis factor blockers in Korean rheumatoid arthritis patients. APLAR Journal of Rheumatology, 2006, 9, 146-149.	0.2	4
247	A functional haplotype of thePADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans. Arthritis and Rheumatism, 2006, 54, 90-96.	6.7	144
248	Cross-cultural adaptation and validation of the Korean fibromyalgia impact questionnaire in women patients with fibromyalgia for clinical research. Quality of Life Research, 2004, 13, 857-861.	3.1	14
249	Association analyses of DNA methyltransferase-1 (DNMT1) polymorphisms with systemic lupus erythematosus. Journal of Human Genetics, 2004, 49, 642-646.	2.3	29
250	Inadequate Antioxidant Nutrient Intake and Altered Plasma Antioxidant Status of Rheumatoid Arthritis Patients. Journal of the American College of Nutrition, 2003, 22, 311-315.	1.8	76